CoChat

Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq

Open access
Alkarkh Hospital, Baghdad, Iraq, Hashim, Hashim, Maulood, Mohammed, Alforat Hospital, Baghdad, Iraq, Ali, Chasib, Alkharkh General Directorate of Health, Baghdad, Iraq, Rasheed, Anwar, Alkharkh General Directorate of Health, Baghdad, Iraq, Fatak, Dhurgham, Alkharkh General Directorate of Health, Baghdad, Iraq, Kabah, Khulood, Alkharkh General Directorate of Health, Baghdad, Iraq, Abdulamir, Ahmed, College of Medicine, Al-Nahrain University, Baghdad, Iraq · 2021 · Iraqi Journal of Medical Sciences

Published version of a preprint

Cited by 98

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200 µg/kg PO of Ivermectin per day for 2-3 days along with 100 mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy, which is (vitamin C, D, and zinc, azithromycin, dexamethasone and oxygen supply if needed). The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters. Among all patients and among severe patients, 3/70 (4.28%) and 1/11 (9%), respectively progressed to a more advanced stage of the disease in the Ivermectin-Doxycycline group versus 7/70 (10%) and 7/22 (31.81%), respectively in the control group (P>0.05). The mortality rate was 0/48 (0%), 0/11 (0%), and 2/11 (18.2%) in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 0/48 (0%), and 6/22 (27.27%) in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (p=0.052). Moreover, the mean time to recovery was 6.34, 20.27, and 24.13 days in mild-moderate, severe, and critical COVID-19 patients, respectively in Ivermectin-Doxycycline group versus 13.66 and 24.25 days in mild-moderate and severe COVID-19 patients, respectively in standard therapy group (P<0.01). It is concluded that Ivermectin with doxycycline reduced the time to recovery, the percentage of patients progress to more advanced stage of disease, and reduced mortality rate in severe patients from 22.72% to 0%. Keywords: Ivermectin, Doxycycline, COVID-19, Coronavirus, SARS-CoV-2 Citation: Hashim HA, Maulood MF, Ali CL, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq Iraqi JMS. 2021; 19(1): 107-115. doi: 10.22578/IJMS.19.1.14

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.22578/ijms.19.1.14

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 98

Metadata

Authors
Alkarkh Hospital, B., Hashim, H., Maulood, M., Alforat Hospital, B., Ali, C., Alkharkh General Directorate of Health, B., Rasheed, A., Alkharkh General Directorate of Health, B., Fatak, D., Alkharkh General Directorate of Health, B., Kabah, K., Alkharkh General Directorate of Health, B., Abdulamir, A., & College of Medicine, A.-N. U.
Venue
Iraqi Journal of Medical Sciences
Published
2021-06-30
Volume
19
Issue
1
Pages
107-115
ISSN
  • 1681-6579 (ISSN-L)
  • 2224-4719
OpenAlex
W4287129885
Cited by
98
References
1
FWCI
6.14
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq. https://app.cochat.ai/papers/10.22578/ijms.19.1.14
The paper
Alkarkh Hospital, B., Hashim, H., Maulood, M., Alforat Hospital, B., Ali, C., Alkharkh General Directorate of Health, B., Rasheed, A., Alkharkh General Directorate of Health, B., Fatak, D., Alkharkh General Directorate of Health, B., Kabah, K., Alkharkh General Directorate of Health, B., Abdulamir, A., & College of Medicine, A.-N. U. (2021). Controlled Randomized Clinical Trial on Using Ivermectin with Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq. Iraqi Journal of Medical Sciences. https://doi.org/10.22578/ijms.19.1.14

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.